Peptic Ulcers – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Peptic Ulcers – Drugs In Development, 2024 report and make more profitable business decisions.
Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach, and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes, and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotics, acid blockers, antacids, and proton pump inhibitors.
The Peptic Ulcers drugs in development market research report provide comprehensive information on the therapeutics under development for Peptic Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Peptic Ulcers | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 28 molecules, with 27 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Peptic Ulcers therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Peptic Ulcers pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Peptic Ulcers treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Addpharma IncAxsome Therapeutics Inc
Boryung Pharmaceutical Co Ltd
CalyGene Biotechnology Inc
Changchun Haiyue Pharmaceutical Co Ltd
Daewoong Co Ltd
Dong Wha Pharma Co Ltd
Dongkwang Pharma Co Ltd
GL Pharm Tech Corp
Hanmi Pharmaceuticals Co Ltd
HEC Pharm Group
Hunan Mingrui Pharmaceutical Co Ltd
Hunan Sailong Pharmaceutical Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Jibeier Pharmaceutical Co Ltd
Jiangsu Sinorda Biomedicine Co Ltd
JW Pharmaceutical Corp
King Saud University
Korea Pharma Co Ltd
Luoxin Pharmaceuticals Group Stock Co Ltd
Onconic Therapeutics Co Ltd
PharmGen Science Inc
R-Pharm
Sebela Pharmaceuticals Inc
Shandong New Time Pharmaceutical Co Ltd
Sotex Pharm Firm
Xiamen Encheng Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Peptic Ulcers reports